I'm here, though I never got an answer on the status of the China FDA application yet. At this point I expect Stellar to gradually grow revenues as they partner with Distribution Companies and their products (Uracyst in particular) become more and more known by doctors/patients.
The big pay day will be if/when Watson gets Uracyst approved for the US, but that will certainly be a long term hold from here. I plan to hold and see if we don't get more recognition as our Revenues grow. Stellar certainly isn't a short-term play, but I think we'll reap the rewards in the future.
News 
Market Data 
Discover 
